악템라(토실리주맙) 시장 보고서(2025년) : 역학, 파이프라인 분석, 시장 인사이트 및 예측

Actemra (Tocilizumab) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

US $ 4,490 ￦ 6,661,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,629,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,596,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

Actemra(토실리주맙) 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년까지 연평균 10%의 성장률로 84억 8,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안의 성장은 코로나19 사이토카인 방출 증후군과 같은 치료 용도의 확대, 맞춤형 의료에 대한 수요 증가, 바이오시밀러의 개발 및 채택, 시장 내 헬스케어 지출 증가, 개발도상국에서의 생물학적 치료에 대한 인식 증가 등에 기인할 것으로 보입니다. 예측 기간 동안 주요 동향으로는 피하주사 제제의 채택 확대, 비용 절감을 위한 바이오시밀러 개발에 대한 관심 증가, 약물 전달 시스템 개선을 위한 바이오테크놀러지의 발전, 새로운 치료 적응증에 대한 임상시험의 진행, 제약사의 전략적 제휴 및 투자 등이 있습니다. 등을 들 수 있습니다.

류마티스 관절염의 유병률 증가는 악템라(토실리주맙) 시장의 성장을 가속할 것으로 예측됩니다. 류마티스 관절염은 만성 자가면역질환으로 관절의 염증과 손상, 삶의 질 저하를 유발하며, 전 세계적으로 수백만 명이 앓고 있는 질환입니다. 흡연, 비만, 환경 노출, 호르몬 영향 등의 요인이 환자 수 증가에 기여하고 있습니다. 악템라(토실리주맙)는 인터루킨-6(IL-6) 수용체를 억제하여 염증을 억제하고 다른 치료에 반응하지 않는 환자의 관절 손상을 예방합니다. 예를 들어, National Institute for Health and Care Research(NIHR)에 따르면 영국에서는 2024년 약 70만 명이 류마티스 관절염을 앓고 있다고 합니다. 또한 호주에서는 호주 보건 복지 연구소가 2022년에는 약 51만 4,000명이 류마티스 관절염을 앓고 있다고 보고하고 있습니다. 따라서 류마티스 관절염 유병률 증가는 악템라(토실리주맙) 시장의 성장을 가속할 것으로 예측됩니다.

액템라(토실리주맙) 시장의 주요 트렌드는 바이오시밀러의 개발이며, 바이오시밀러는 오리지널 의약품을 대체할 수 있는 보다 저렴한 대체품을 의미합니다. 바이오시밀러 의약품은 자가면역질환 치료제로 승인되었으며, 오리지널 의약품인 악템라와 유사한 효과를 나타냅니다. 예를 들어, 프레제니우스 카비는 2023년 11월 유럽연합(EU)에서 RoActemra(tocilizumab)를 참조하는 최초의 tocilizumab 바이오시밀러인 Tyenne을 출시했습니다. 타이엔은 류마티스 관절염, 거대세포 동맥염, 사이토카인 방출 증후군(CRS) 등 여러 염증성 및 면역질환 치료제로 승인됐습니다. 이번 개발로 시장 경쟁이 치열해져 보다 저렴한 비용으로 더 많은 치료 옵션이 제공될 것으로 기대됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 바이오의약품 시장 제품 특성

• 분자 유형
• 투여 경로(ROA)
• 작용기전(MOA)
• 안전성과 유효성

제4장 시장 동향과 전략

제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스, 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제6장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 악템라(토실리주맙) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 악템라(토실리주맙) 시장 : 성장률 분석
• 세계의 악템라(토실리주맙) 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 악템라(토실리주맙) 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 악템라(토실리주맙) : 전체 잠재 시장 규모(TAM)

제7장 세계 시장 가격 분석과 예측

제8장 시장 세분화

• 세계의 악템라(토실리주맙) 시장 : 제품 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 최저 순도 98% 이하
• 최저 순도 98-99%
• 최저 순도 99% 이상
• 세계의 악템라(토실리주맙) 시장 : 투여량별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 주사
• 용액
• 농축물
• 세계의 악템라(토실리주맙) 시장 : 투여 경로별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 경구
• 비경구
• 기타
• 세계의 악템라(토실리주맙) 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원 약국
• 소매 약국
• 온라인 약국
• 세계의 악템라(토실리주맙) 시장 : 용도별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 사이토카인 방출 증후군(CRS)
• 전신성 소아특발성 관절염(sJIA)
• 거대세포 동맥염(GCA)
• 류마티스 관절염(RA)

제9장 임상 적응증 세계 시장 역학

• 약제 부작용
• 임상 적응증 발증률과 유병률

제10장 지역별/국가별 분석

• 세계의 악템라(토실리주맙) 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 악템라(토실리주맙) 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 경쟁 구도와 기업 개요

• 악템라(토실리주맙) 시장 : 경쟁 구도
• 악템라(토실리주맙) 시장 : 기업 개요
  • Roche Holding AG
  • Fresenius Kabi

제29장 세계 시장 : 파이프라인 분석

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 최근 시장 동향

제33장 시장 잠재력이 높은 국가, 전략

• 악템라(토실리주맙) 시장, 2029년 : 새로운 기회를 제공하는 국가
• 악템라(토실리주맙) 시장, 2029년 : 새로운 기회를 제공하는 부문
• 악템라(토실리주맙) 시장, 2029년 : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제34장 부록

LSH

영문 목차

영문목차

Actemra (Tocilizumab) is a prescription biologic medication classified as an interleukin-6 (IL-6) receptor antagonist, used to treat various autoimmune and inflammatory conditions. It works by inhibiting IL-6, a cytokine involved in inflammation, which helps reduce symptoms and prevent disease progression in conditions such as rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary product types of actemra (tocilizumab) are categorized by purity levels less than 98%, between 98% and 99%, and more than 99%. The less than 98% purity includes tocilizumab products that may have more impurities or residual components, potentially affecting efficacy and safety. The dosages available are injection, solution, and concentrate, with routes of administration including oral, parenteral, and others. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Actemra is used in various applications such as cytokine release syndrome (CRS), systemic juvenile idiopathic arthritis (SJIA), giant cell arteritis (GCA), and rheumatoid arthritis (RA).

The actemra (tocilizumab) market research report is one of a series of new reports from The Business Research Company that provides actemra (tocilizumab) market statistics, including actemra (tocilizumab) industry global market size, regional shares, competitors with a actemra (tocilizumab) market share, detailed actemra (tocilizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the actemra (tocilizumab) industry. This actemra (tocilizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The actemra (tocilizumab) market size is expected to see rapid growth in the next few years. It will grow to $8,480.0 million in 2029 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to the expansion of therapeutic applications, such as COVID-19 cytokine release syndrome, growing demand for personalized medicine, development and adoption of biosimilars, rising healthcare expenditure in emerging markets, and increasing awareness of biologic therapies in developing regions. Major trends in the forecast period include increasing adoption of subcutaneous formulations, growing focus on biosimilar development for cost reduction, advancements in biotechnology for improved drug delivery systems, ongoing clinical trials for new therapeutic indications, and strategic partnerships and investments by pharmaceutical companies.

The rising prevalence of rheumatoid arthritis is expected to propel the growth of the actemra (tocilizumab) market. Rheumatoid arthritis is a chronic autoimmune condition that leads to joint inflammation, damage, and reduced quality of life, affecting millions globally. Factors such as smoking, obesity, environmental exposures, and hormonal influences contribute to the rise in cases. Actemra (tocilizumab) works by inhibiting the interleukin-6 (IL-6) receptor, reducing inflammation, and preventing joint damage in patients who have not responded to other treatments. For instance, according to the National Institute for Health and Care Research (NIHR), approximately 700,000 people in the UK were living with rheumatoid arthritis in 2024. Additionally, in Australia, the Australian Institute of Health and Welfare reported that approximately 514,000 people were living with the condition in 2022. Therefore, the increasing prevalence of rheumatoid arthritis is expected to drive the growth of the actemra (tocilizumab) market.

A key trend in the actemra (tocilizumab) market is the development of biosimilars, which provide a more affordable alternative to the original drug. Biosimilars are approved to treat autoimmune diseases, offering similar efficacy to the originator drug, Actemra. For example, in November 2023, Fresenius Kabi launched Tyenne, the first tocilizumab biosimilar referencing RoActemra (tocilizumab) in the European Union. Tyenne is approved for treating multiple inflammatory and immune diseases, including rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome (CRS). This development is expected to increase market competition and provide more treatment options at lower costs.

In September 2024, Bio-Thera Solutions Ltd., a China-based biopharmaceutical company, partnered with Biogen Inc. to publish Phase 3 clinical trial data for TOFIDENCE (BAT1806/BIIB800), a biosimilar to Actemra. TOFIDENCE aims to expand treatment access for autoimmune conditions. Biogen Inc. is a US-based biotechnology company specializing in therapies for neurological and autoimmune diseases. This partnership is set to enhance the growth of the Actemra market by broadening treatment options and improving access to affordable therapies.

Major players operating in the actemra (tocilizumab) market are Roche Holding AG; Fresenius Kabi

North America was the largest region in the actemra (Tocilizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in actemra (tocilizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the actemra (tocilizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The actemra (tocilizumab) market consists of sales of intravenous (IV) and subcutaneous (SC) formulations used to treat autoimmune and inflammatory diseases. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Actemra (Tocilizumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on actemra (tocilizumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for actemra (tocilizumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The actemra (tocilizumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Min Purity Less Than 98%; Min Purity 98%-99%; Min Purity More Than 99%
• 2) By Dosage: Injection; Solution; Concentrate
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 5) By Application: Cytokine Release Syndrome (CRS); Systemic Juvenile Idiopathic Arthritis (sJIA); Giant Cell Arteritis (GCA); Rheumatoid Arthritis (RA)
• Companies Mentioned: Roche Holding AG; Fresenius Kabi
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Actemra (Tocilizumab) Market Characteristics

3. Actemra (Tocilizumab) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Actemra (Tocilizumab) Market Trends And Strategies

5. Actemra (Tocilizumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Actemra (Tocilizumab) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Actemra (Tocilizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Actemra (Tocilizumab) Market Growth Rate Analysis
• 6.4. Global Actemra (Tocilizumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Actemra (Tocilizumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Actemra (Tocilizumab) Total Addressable Market (TAM)

7. Global Actemra (Tocilizumab) Market Pricing Analysis & Forecasts

8. Actemra (Tocilizumab) Market Segmentation

• 8.1. Global Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Min Purity Less Than 98%
• Min Purity 98%-99%
• Min Purity More Than 99%
• 8.2. Global Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection
• Solution
• Concentrate
• 8.3. Global Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 8.4. Global Actemra (Tocilizumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 8.5. Global Actemra (Tocilizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cytokine Release Syndrome (CRS)
• Systemic Juvenile Idiopathic Arthritis (sJIA)
• Giant Cell Arteritis (GCA)
• Rheumatoid Arthritis (RA)

9. Global Actemra (Tocilizumab) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Actemra (Tocilizumab) Market Regional And Country Analysis

• 10.1. Global Actemra (Tocilizumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Actemra (Tocilizumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Actemra (Tocilizumab) Market

• 11.1. Asia-Pacific Actemra (Tocilizumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Actemra (Tocilizumab) Market

• 12.1. China Actemra (Tocilizumab) Market Overview
• 12.2. China Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Actemra (Tocilizumab) Market

• 13.1. India Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Actemra (Tocilizumab) Market

• 14.1. Japan Actemra (Tocilizumab) Market Overview
• 14.2. Japan Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Actemra (Tocilizumab) Market

• 15.1. Australia Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Actemra (Tocilizumab) Market

• 16.1. South Korea Actemra (Tocilizumab) Market Overview
• 16.2. South Korea Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Actemra (Tocilizumab) Market

• 17.1. Western Europe Actemra (Tocilizumab) Market Overview
• 17.2. Western Europe Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Actemra (Tocilizumab) Market

• 18.1. UK Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Actemra (Tocilizumab) Market

• 19.1. Germany Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Actemra (Tocilizumab) Market

• 20.1. France Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Actemra (Tocilizumab) Market

• 21.1. Eastern Europe Actemra (Tocilizumab) Market Overview
• 21.2. Eastern Europe Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Actemra (Tocilizumab) Market

• 22.1. North America Actemra (Tocilizumab) Market Overview
• 22.2. North America Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Actemra (Tocilizumab) Market

• 23.1. USA Actemra (Tocilizumab) Market Overview
• 23.2. USA Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Actemra (Tocilizumab) Market

• 24.1. Canada Actemra (Tocilizumab) Market Overview
• 24.2. Canada Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Actemra (Tocilizumab) Market

• 25.1. South America Actemra (Tocilizumab) Market Overview
• 25.2. South America Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Actemra (Tocilizumab) Market

• 26.1. Middle East Actemra (Tocilizumab) Market Overview
• 26.2. Middle East Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Actemra (Tocilizumab) Market

• 27.1. Africa Actemra (Tocilizumab) Market Overview
• 27.2. Africa Actemra (Tocilizumab) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Actemra (Tocilizumab) Market, Segmentation By Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Actemra (Tocilizumab) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Actemra (Tocilizumab) Market Competitive Landscape And Company Profiles

• 28.1. Actemra (Tocilizumab) Market Competitive Landscape
• 28.2. Actemra (Tocilizumab) Market Company Profiles
  • 28.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. Fresenius Kabi Overview, Products and Services, Strategy and Financial Analysis

29. Global Actemra (Tocilizumab) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Actemra (Tocilizumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Actemra (Tocilizumab) Market

32. Recent Developments In The Actemra (Tocilizumab) Market

33. Actemra (Tocilizumab) Market High Potential Countries, Segments and Strategies

• 33.1 Actemra (Tocilizumab) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Actemra (Tocilizumab) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Actemra (Tocilizumab) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer

관련자료